- Home
- AHG vs TBPH Comparison
AHG vs TBPH Comparison
Compare AHG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- TBPH
- Stock Information
- Founded
- AHG 2013
- TBPH 2013
- Country
- AHG China
- TBPH United States
- Employees
- AHG N/A
- TBPH N/A
- Industry
- AHG Business Services
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- TBPH Health Care
- Exchange
- AHG Nasdaq
- TBPH Nasdaq
- Market Cap
- AHG 752.4M
- TBPH 699.0M
- IPO Year
- AHG N/A
- TBPH N/A
- Fundamental
- Price
- AHG $1.51
- TBPH $18.46
- Analyst Decision
- AHG
- TBPH Strong Buy
- Analyst Count
- AHG 0
- TBPH 4
- Target Price
- AHG N/A
- TBPH $24.25
- AVG Volume (30 Days)
- AHG 10.4K
- TBPH 523.4K
- Earning Date
- AHG 12-15-2025
- TBPH 11-10-2025
- Dividend Yield
- AHG N/A
- TBPH N/A
- EPS Growth
- AHG N/A
- TBPH N/A
- EPS
- AHG N/A
- TBPH 0.58
- Revenue
- AHG $14,777,798.00
- TBPH $80,327,000.00
- Revenue This Year
- AHG N/A
- TBPH $79.82
- Revenue Next Year
- AHG N/A
- TBPH N/A
- P/E Ratio
- AHG N/A
- TBPH $32.31
- Revenue Growth
- AHG 512.09
- TBPH 27.12
- 52 Week Low
- AHG $0.74
- TBPH $7.90
- 52 Week High
- AHG $2.35
- TBPH $18.96
- Technical
- Relative Strength Index (RSI)
- AHG 45.04
- TBPH 66.84
- Support Level
- AHG $1.33
- TBPH $17.50
- Resistance Level
- AHG $1.56
- TBPH $18.58
- Average True Range (ATR)
- AHG 0.09
- TBPH 1.00
- MACD
- AHG 0.00
- TBPH 0.17
- Stochastic Oscillator
- AHG 35.94
- TBPH 89.38
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).